Table 2 Clinicopathologic characteristics of high-risk patients

Median age [IQR]

40.5 [35.0;51.0]

39.0 [35.0;50.0]

41.0 [37.0;51.0]

Ovary cancer

 Yes

7 (4.4%)

15 (1.8%)

16 (0.5%)

 No

151 (95.6%)

800 (98.2%)

3504 (99.5%)

Family history

 Yes

116 (73.4%)

421 (51.7%)

761 (21.6%)

 No

40 (25.3%)

386 (47.4%)

2631 (74.7%)

 Unknown

2 (1.3%)

8 (1.0%)

128 (3.6%)

Family history of breast cancer

 Yes

103 (65.2%)

403 (49.4%)

667 (18.9%)

 No

53 (33.5%)

404 (49.6%)

2725 (77.4%)

 Unknown

2 (1.3%)

8 (1.0%)

128 (3.6%)

First-degree relative with breast cancer

 Yes

79 (50.0%)

336 (41.2%)

457 (13.0%)

 No

76 (48.1%)

471 (57.8%)

2931 (83.3%)

 Unknown

3 (1.9%)

8 (1.0%)

132 (3.8%)

T stage

 T1

60 (38.0%)

366 (44.9%)

1472 (41.8%)

 T2

83 (52.5%)

376 (46.1%)

1679 (47.7%)

 T3

9 (5.7%)

51 (6.3%)

261 (7.4%)

 T4

5 (3.2%)

21 (2.6%)

101 (2.9%)

 Unknown

1 (0.6%)

1 (0.1%)

7 (0.2%)

N stage

 N0

78 (49.4%)

445 (54.6%)

1955 (55.5%)

 N1

47 (29.7%)

226 (27.7%)

963 (27.4%)

 N2

19 (12.0%)

90 (11.0%)

402 (11.4%)

 N3

13 (8.2%)

52 (6.4%)

183 (5.2%)

 Unknown

1 (0.6%)

2 (0.2%)

17 (0.5%)

Histologic grade

 1

4 (2.5%)

69 (8.5%)

180 (5.1%)

 2

50 (31.6%)

402 (49.3%)

1260 (35.8%)

 3

97 (61.4%)

308 (37.8%)

1834 (52.1%)

 9

7 (4.4%)

36 (4.4%)

246 (7.0%)

Lymphovascular invasion

 Present

53 (33.5%)

248 (30.4%)

1108 (31.5%)

 None

99 (62.7%)

537 (65.9%)

2250 (63.9%)

 Unknown

6 (3.8%)

30 (3.7%)

162 (4.6%)

Subtype

 HR+/HER2−

75 (47.5%)

488 (59.9%)

1457 (41.4%)

 HR+/HER2+

6 (3.8%)

112 (13.7%)

288 (8.2%)

 HR−/HER2+

6 (3.8%)

53 (6.5%)

204 (5.8%)

 HR−/HER2−

71 (44.9%)

162 (19.9%)

1571 (44.6%)